The impact of elevated serum IgA and race on primary recipient renal allograft survival

Transplantation
B M SusskindB D Kahan

Abstract

This study correlated overall serum IgA levels in pretransplant (preTx) sera with graft survival. IgA levels, determined by nephelometry, were normally distributed, with a mean level of 255 +/- 139 mg/dl and a median of 234 mg/dl in 631 adult primary kidney allograft recipients and a mean level of 213 +/- 123 mg/dl with a median of 196 mg/dl for 100 retransplant recipients. Improved 3-year survival was associated with a high preTx IgA serum level in primary recipients (Kaplan-Meier analysis, P = 0.01), but not in retransplant patients. After stratifying by race, IgA correlated with graft survival in Caucasian, Hispanic, and "other" (Middle Eastern, Indian subcontinent, and Asian) primary recipients (P < or = 0.04), but not in African Americans. Higher survival rates were not associated with IgA in primary recipients stratified for rejection episodes, blood transfusions, or HLA-DR mismatches. Graft survival was improved in patients with > 2 HLA-AB mismatches and serum IgA above the median. PreTx IgA level and IgA alpha-HLA activity were significantly associated in preTx sera of primary renal allograft recipients (chi 2 = 7.145, P = 0.01), although only 9% (12/133) of sera tested displayed IgA anti-HLA class I reactivity. Thus, e...Continue Reading

References

Jun 1, 1991·Kidney International·P A Crowley-NowickS Jackson
Nov 1, 1969·Transplantation·G A VoisinC Bernard
Jan 1, 1980·Transplantation·W C Davis, I F McKenzie
Apr 1, 1993·Immunology Letters·C SüsalG Opelz
Apr 1, 1994·International Journal of Cancer. Journal International Du Cancer·C SüsalG Opelz
Oct 1, 1993·Journal of Autoimmunity·C SüsalG Opelz

❮ Previous
Next ❯

Citations

Dec 1, 1999·Transplantation Proceedings·A MorgunM Gerbase-DeLima
Jul 17, 2010·Clinical Journal of the American Society of Nephrology : CJASN·M Colleen HastingsRobert J Wyatt
May 3, 2011·Journal of Immunological Methods·Hooi Sian Eng, Mary S Leffell
Jan 3, 2013·International Journal of Immunogenetics·M-L ArnoldB M Spriewald
Jun 4, 2015·Transplantation Proceedings·M A AmirzargarG Solgi
Apr 27, 2020·Clinical Transplantation·Zane C GiffenJorge Ortiz
Jun 26, 1999·Clinical Transplantation·M BunkeB Ketel
Mar 27, 2018·International Journal of Immunogenetics·M-L ArnoldB M Spriewald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.